News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Oil prices retreated after three days of gains as a fragile Iran ceasefire faltered.
  • U.S. dollar strengthened to a near one-week high after consumer inflation surprised to the upside.
  • Gold held ground as prospects for a U.S.-Iran deal dimmed.
  • The Trump Organization terminated a planned A$1.5 billion Gold Coast skyscraper after its Australian partner allegedly defaulted.
  • Ring Energy priced a roughly $60 million common stock offering at $1.35 per share to repay revolver borrowings.
  • Breeze Acquisition Corp. II priced a $125 million IPO to target global healthcare, biotech, robotics and AI deals.
  • Incoming BHP CEO Brandon Craig signaled a push for growth beyond 2035 via increased exploration and targeted, smaller acquisitions.

Latest Articles

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau Medical Ltd. announced groundbreaking interim results from their U.S. trial of Alpha DaRT therapy in patients with recurrent glioblastoma. Among the first three patients treated, two showed complete responses with total tumor disappearance, while the third had stable disease and tumor reduction. The treatment was generally well tolerated …

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health received authorization to start a Phase 1/2 clinical trial of RJVA-001, its first gene therapy candidate aimed at treating type 2 diabetes by enabling nutrient-responsive GLP-1 expression in the pancreas. This marks the company's advancement to a dual clinical-stage biotech, with RJVA-001 being the first adeno-associated virus-based …

Hain Celestial Reports Fiscal Third Quarter 2026 Financial Results

Hain Celestial Reports Fiscal Third Quarter 2026 Financial Results

Hain Celestial announced its fiscal third quarter 2026 financial results, reporting a 13% year-over-year decline in net sales to $338 million, with organic net sales down 6%. Despite lower revenues and a net loss of $106 million driven partly by asset impairments and the sale of its North American snacks business, the company improved its financial…

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics announced FDA clearance for an IND to begin Phase 1/2 clinical trials of their oral elraglusib formulation in advanced cancers including metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, aiming to improve patient convenience and drug exposure. The company also revealed plans to study elraglusib in combination with…

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences announced preclinical data demonstrating the potential of fatty acid synthase (FASN) inhibitors to reduce sebum production, a key factor in acne. This supports their upcoming Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S., planned to initiate in the second half of 2026. The data will be presented a…

RoboStrategy, Inc. Lists on NASDAQ Under Ticker “BOT”, Enabling Investors to Access a Portfolio of Robotics and Physical AI Companies in a Single Stock

RoboStrategy, Inc. Lists on NASDAQ Under Ticker “BOT”, Enabling Investors to Access a Portfolio of Robotics and Physical AI Companies in a Single Stock

RoboStrategy, Inc., a closed-end investment fund focusing on robotics and physical AI companies, has begun trading on the NASDAQ under the ticker BOT. The fund offers public investors exposure to a concentrated portfolio of private, pre-IPO, and public robotics firms, bridging the gap between venture capital opportunities and public markets. This d…

Kaspi.kz 1Q 2026 Financial Results

Kaspi.kz 1Q 2026 Financial Results

Kaspi.kz announced robust financial results for Q1 2026 with a 41% year-over-year growth in e-Commerce gross merchandise value and a 9% increase in adjusted EBITDA. The company highlighted increased consumer purchase frequency and improved monetization, particularly in advertising and delivery services. Kaspi.kz is expanding internationally with si…

EU Executive Enters Separate Talks with OpenAI and Anthropic Over Model Access

EU Executive Enters Separate Talks with OpenAI and Anthropic Over Model Access

The European Commission is engaged in separate conversations with US artificial intelligence developers OpenAI and Anthropic. OpenAI has proactively offered to grant the Commission access to its new AI model, while the Commission has held multiple meetings with Anthropic but has not yet reached discussions about model access, a spokesperson said.

Blackstone to Buy Greek Online Retailer Skroutz From CVC

Blackstone to Buy Greek Online Retailer Skroutz From CVC

Blackstone has agreed to acquire Greek e-commerce platform Skroutz from CVC Capital Partners Fund VII in a transaction that values the company, including debt, at about 635 million euros. CVC is set to double its initial investment, and the platform's founders will sell part of their stake while keeping a share and continuing to lead operations und…

Eleventh Week of Iran Tensions Keeps Energy and Markets on Edge

Eleventh Week of Iran Tensions Keeps Energy and Markets on Edge

The Iran conflict has reached its 11th week with no clear resolution, keeping the Strait of Hormuz effectively closed to oil and cargo shipping and lifting oil prices. Markets have shown resilience, aided by tech and chip strength, but inflation readings, U.S. labor data and geopolitical risks may introduce new stress to growth and prices this week…

OLAPLEX Reports First Quarter 2026 Results

OLAPLEX Reports First Quarter 2026 Results

Olaplex Holdings, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a 2.5% increase in net sales to $99.4 million but a net loss of $5.3 million compared to net income in the prior year period. The company highlighted positive sales trends driven by the launch of No. 3 PLUS and progress in its transformation…

HSBC Raises S&P 500 Target to 7,650 Citing Strong Earnings Momentum

HSBC Raises S&P 500 Target to 7,650 Citing Strong Earnings Momentum

HSBC increased its year-end S&P 500 target from 7,500 to 7,650, citing resilient corporate earnings—particularly concentrated among large technology firms tied to AI. The bank projects roughly 20% earnings-per-share growth for 2026 and notes that the index has delivered strong recent gains, although it warns that sentiment is fragile and the rally …